Royalty Pharma (RPRX) Long-Term Investments (2019 - 2026)
Royalty Pharma (RPRX) posted Long-Term Investments of $265.7 million for Q1 2026, up 55.1% sequentially from $171.3 million in Q4 2025, and up 88.33% YoY from $141.1 million in Q1 2025.
Royalty Pharma (RPRX) Long-Term Investments (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Long-Term Investments for 8 years, with the latest figure at $265.7 million in Q1 2026.
- Quarterly Long-Term Investments rose 88.33% year-over-year to $265.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $265.7 million (up 88.33% YoY) and the FY2025 annual result came in at $171.3 million, down 54.85% from the prior year.
- Long-Term Investments improved to $265.7 million in Q1 2026 per RPRX's latest filing, from $171.3 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $409.9 million in Q3 2022 and troughed at $63.0 million in Q2 2022.
- A 5-year average of $253.6 million and a median of $267.2 million in 2023 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2022 and 2023: Long-Term Investments plunged 68.89% in 2022, then jumped 126.67% in 2023.
- Over 5 years, Long-Term Investments stood at $226.3 million in 2022, then jumped by 66.1% to $375.9 million in 2023, then grew by 0.94% to $379.4 million in 2024, then slumped by 54.85% to $171.3 million in 2025, then jumped by 55.1% to $265.7 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $265.7 million, $171.3 million, and $291.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 372.10 Mn |
| Mar 31, 2026 | 265.70 Mn |
| Dec 31, 2025 | 171.31 Mn |
| Sep 30, 2025 | 290.96 Mn |
| Jun 30, 2025 | 271.90 Mn |
| Mar 31, 2025 | 141.08 Mn |
| Dec 31, 2024 | 379.42 Mn |
| Sep 30, 2024 | 228.87 Mn |
| Jun 30, 2024 | 178.02 Mn |
| Mar 31, 2024 | 277.22 Mn |
| Dec 31, 2023 | 375.89 Mn |
| Sep 30, 2023 | 353.60 Mn |
| Jun 30, 2023 | 142.80 Mn |
| Mar 31, 2023 | 267.20 Mn |
| Dec 31, 2022 | 226.30 Mn |
| Sep 30, 2022 | 409.86 Mn |
| Jun 30, 2022 | 63.00 Mn |
| Mar 31, 2022 | 267.64 Mn |
| Dec 31, 2021 | 269.80 Mn |
| Sep 30, 2021 | 264.77 Mn |